Nephros On-line Mid-Dilution Hemodiafiltration System
|
|
- Silas Lamb
- 5 years ago
- Views:
Transcription
1 _PO Nephros On-line Mid-Dilution Hemodiafiltration System Clinicians Overview with Safety and Efficacy Summary Note: Federal (USA) law restricts these devices to sale by or on the order of a physician. For further information contact: Nephros, Inc. 380 Lackawanna Place South Orange, NJ USA Telephone: Fax: Web:
2 Purpose This document provides a potential clinician, user or reviewer with a brief summary of the Nephros On-line Mid-Dilution Hemodiafiltration (HDF) System and its components with salient comparisons between hemodialysis and hemodiafiltration. Also included are clinic requirements needed to use the Nephros On-line Mid-Dilution HDF System and a summary of safety and efficacy results obtained as part of a clinical investigational study with the Nephros system. Introduction to HDF Hemodiafiltration (HDF) is a renal replacement therapy that combines hemodialysis (solutes cleared primarily by diffusion) with hemofiltration (solutes primarily cleared by filtration or convection). During HDF, toxin rich plasma water is ultrafiltered across the dialyzer membrane and into the spent dialysate at rates of 100 to 300 ml/min (or 6 to 18 liters/hour). The increased ultrafiltration that occurs with HDF generally increases the clearance of uremic toxins, especially larger, middle molecular weight toxins, as these toxins are carried or dragged across the membrane as part of the %ow of ultrafiltered plasma water. To keep the patient in proper %uid balance, a substitution %uid must be continuously infused into the extracorporeal circuit to replace the plasma water that is being filtered out of the patient s blood as it passes through the hemodiafilter device. On-line HDF refers to the method which produces the substitution %uid used during hemodiafiltration. In particular, in on-line HDF, substitution %uid is generated in real time using a portion of the dialysate produced by the dialysis machine. This is accomplished by redirecting some of the fresh dialysate and passing it through a series of redundant ultrafilters. These ultrafilters remove microbiologic contaminants (bacteria and endotoxin) from the dialysate before it is infused into the blood circuit as a substitution %uid. On-line HDF using redundant ultrafilters to purify the dialysate for infusion is actively used in Europe. Nephros has developed the OLpūr Hemodiafiltration H 2 H Module) that works using the same principles as the European on-line HDF machines; however, it has been designed as a separate (standalone) device that works in conjunction with a standard ultrafiltration-controlled hemodialysis machine to generate on-line substitution %uid. Nephros has also developed a unique hemodiafilter (OLpūr MD 220 Hemodiafilter) that overcomes the limitations observed with pre- and post-dilution HDF using a standard high-%ux dialyzer. The device is similar to a standard dialyzer but uses modified blood header caps to create a simple two-stage design whereby the substitution %uid is infused in a mid-dilution configuration as blood moves between the two stages of the device. Further details of the Nephros OLpūr H 2 H Module and the OLpūr MD 220 Hemodiafilter are provided in the device description section of this document. 2 Nephros On-line Mid-Dilution Hemodiafiltration System
3 What is needed to perform HDF with the Nephros On-line Mid-Dilution Hemodiafiltration System? Indications for Use Contraindications Dialysis quality water meeting the current ANSI/AAMI/ISO standard Ultrapure dialysate meeting the current ANSI/AAMI/ISO standard The Nephros OLpūr MD 220 Hemodiafilter (MD 220 filter) The Nephros OLpūr H 2 H Hemodiafiltration Module (H 2 H Module) An H 2 H compatible host hemodialysis machine (ultrafiltration-controlled) All accessory components for the Nephros H 2 H Module The OLpūr H 2 H Hemodiafiltration Module is indicated for use, with a UF-controlled hemodialysis machine that provides ultrapure dialysate in accordance with the current ANSI/AAMI/ISO standards, for treatment of patients with chronic renal failure as prescribed by a physician. The OLpūr MD 220 Hemodiafilter is indicated for use for hemodiafiltration of patients with chronic renal failure. There are no absolute contraindications to HDF; however, HDF should be avoided or applied with extreme caution in patients with the following conditions or circumstances: Unable to receive or contraindications to adequate anticoagulation Hypercoagulation syndromes Hyperviscosity syndromes Pre-treatment Hematocrit 40% Single-Needle blood access Blood access with obvious recirculation Description of the Nephros On-line Mid-Dilution HDF System The Nephros OLpūr H 2 H Module H Module is a so(ware controlled electromechanical medical device designed to work in conjunction with an approved hemodialysis machine. H Module offers a simple way to enhance the functionality of a clinic s existing hemodialysis machine by enabling approved machines to be used to perform on-line HDF. H Module is a freestanding device on a Clinicians Overview with Safety and Efficacy Summary 3
4 movable stand that is placed next to the host dialysis machine. H Module must be connected to the clinic s water supply, drain and electricity. H Module serves two basic functions. The primary function is to generate on-line substitution %uid for HDF. During the course of an HDF treatment, the H 2 H Module is continuously monitoring the dialysate %ow, blood %ow, and for any evidence of blood contamination back into its onboard substitution %uid filter. H Module s secondary function is to serve as a substitution %uid and water filter reprocessing system that automates management of the H 2 H Module s dialysate purification system. H Module may be used only with approved Nephros accessory components (i.e. H 2 H Substitution filter, H 2 H Water filter, and H 2 H Infusion line). Only compatible host dialysis machine models can be used as indicated in the Nephros OLpūr H 2 H Module User s Manual. Accessory Components for the H 2 H Module H Substitution Fluid Filter H Substitution filter is a hollow fiber, ultrafilter device that consists of two sequential (redundant) ultrafiltration stages in a single housing. During on-line HDF with the H 2 H Module, fresh dialysate is redirected by the H 2 H Module s hydraulic (substitution) pump and passed through this dual-stage ultrafilter before being infused as substitution %uid into the extracorporeal circuit. H Substitution filter remains on the H 2 H Module for 14 days and is removed from the H 2 H Module when its useful life has expired or if it has failed a filter integrity test performed by the H 2 H Module. If the H 2 H Substitution filter is not properly disinfected at least once every 72 hours by running a complete Filter Care routine, the Module s HDF treatment functions will be disabled, thereby prohibiting the user to perform online HDF with the H 2 H Module until a successful Filter Care routine has been completed. H Infusion Line H Infusion line is a sterile, single-use, disposable tubing set that is replaced a(er each patient treatment. During on-line HDF, the H 2 H Infusion line connects the outlet port of the H 2 H Substitution filter to the substitution port on the Nephros MD 220 hemodiafilter. H Infusion line contains a detachable tubing segment (the rinse line) that contains a one-way check valve. During reprocessing of the H 2 H Substitution filter, the distal portion of the rinse line is disconnected from the rest of the infusion set and is re-connected to a dedicated rinse port on the front of the H 2 H Module. The one-way check valve, in addition to a so(ware controlled pinch valve on the H 2 H Module, ensures that %uid (patient s blood) cannot %ow backward to contaminate the H 2 H Substitution filter. 4 Nephros On-line Mid-Dilution Hemodiafiltration System
5 H Water Filter H Water filter is a single stage ultrafilter. All water the H 2 H Module uses for rinsing, priming and disinfection of the %uid path, including the H 2 H Substitution filter, must %ow through this filter before entering the H 2 H Module. H Water filter is a hollow fiber, membrane-type ultrafilter that is designed for continuous use over a 2 week (14 day) period when subjected to daily functional and structural integrity testing as part of H 2 H Module s normal operation. The OLpūr MD 220 Hemodiafilter Nephros has developed a unique hemodiafilter, the OLpūr MD 220 Hemodiafilter, to overcome limitations caused by using a standard high-%ux dialyzer for hemodiafiltration. The MD 220 is very similar to a typical hollow fiber dialyzer assembled with a single hollow fiber bundle made with a high-%ux (or high-permeability) membrane. At one end of the device, however, is a blood header cap having both a blood inlet port and a blood outlet port. The two-port cap has an internal dividing wall that inserts into a ringshaped groove in the potting compound. A mechanical seal is formed that separates the incoming blood from the exiting blood at this end of the device. As a result, the fiber bundle is separated into two discrete but serially connected blood paths: an outer or annular path (Stage 1), and an inner or core path (Stage 2). At the opposite end of the device is the substitution header cap, which allows for the infusion of substitution %uid and subsequent mixing with the blood as it moves between the two stages (i.e. in a middilution hemodiafiltration mode). Clinicians Overview with Safety and Efficacy Summary 5
6 Theory of Operation of the Nephros On-line Mid-Dilution Hemodiafiltration System The Volumetrically Static Dialysate Path The dialysate path of a dialysis machine that is capable of functioning as host machine for the H 2 H Module must behave as if it were a closed system relative to the expansion or contraction of its dialysate %uid volume. The dialysis machines that accomplish this are based on mechanical %uid balancing chambers or %ow measuring devices in feed-back loops with %ow control pumps. These ultrafiltration (UF) control systems are isovolumetric and assure that the volume of dialysate produced by the machine (fresh dialysate) is essentially equivalent to the volume of dialysate returned to the machine (spent dialysate). It is noted that a small difference between inlet and outlet dialysate %ows is necessary when a net amount of %uid is removed from the patient to reach their dry weight. This, however, is a normal function of a UF-controlled dialysis machine whereby the user enters a net volume of %uid to be removed from the patient (see section below). The Volumetrically Variable Patient The patient, in contrast to the above, does not behave as a closed %uid compartment. Fluid status of a patient can change in several ways which include the insensible net %uid loss from breathing and perspiration versus the net gain through drinking, saline infusion, and eating. During treatment of patients, it is generally necessary to remove %uid from the patient to offset the net gain of %uid and to return the patient to their dry weight. This removal of %uid during treatment is accomplished as a net loss through ultrafiltration of plasma water across the dialyzer membrane. Introducing the H 2 H Module into the Dialysate Path To accomplish on-line HDF with the H 2 H Module, the H 2 H Module is introduced as part of the closed dialysate path. As dialysate is removed from the closed dialysate path by the H 2 H Module as illustrated below, the UF-control system of the host dialysis machine responds automatically by demanding an identical volume of plasma water (containing uremic toxins) to be forward filtered out of the blood and into the dialysate compartment of the hemodiafilter. This to assure the volume of spent dialysate returning to the host dialysis machine is the same as the volume of fresh dialysate it delivered to the H 2 H Module and subsequently to the dialysate compartment of the hemodiafilter. The dialysate %uid that was removed from the closed dialysate path is purified by the H 2 H Module by redundant ultrafiltration through its onboard substitution filter, and infused directly into the extracorporeal circuit as on-line replacement (substitution) %uid. The net effect is that plasma water containing the uremic toxins is transferred from the blood compartment to the dialysate compartment where it combines with the spent dialysate %uid being returned to the host dialysis machine in exchange for clean purified dialysate passing through the H 2 H Substitution filter of the H 2 H Module and into the extracorporeal circuit. The host dialysis machine, controlled by user input, has complete authority over the dialysate production and dialysate %ow rate. H Module User s Manual requires a minimum dialysate %ow rate of 500 ml/min on procedures prior to starting the HDF treatment and recommends a minimum dialysate %ow rate of 600 ml/min during the 6 Nephros On-line Mid-Dilution Hemodiafiltration System
7 HDF treatment when using the H 2 H Module in conjunction with the host dialysis machine. These %ow rates are within the range of dialysate %ow used in clinical practice and therefore do not require a shi( in normal management of the host s dialysate concentrate needs. The current recommended clinical practice with regard to dialysate concentrate is for the user to provide sufficient concentrate to complete the treatment at the user commanded dialysate %ow rate before starting the treatment. Note that all references to dialysate %ow rate or Q d refer to the value for dialysate %ow set on the host dialysis machine. This value (e.g. 800 ml/min) is also the dialysate %ow rate that exits the MD 220 filter and is returned to the host machine as spent dialysate. In conventional dialysis this is also the dialysate %ow rate entering the dialyzer. However, in the Nephros HDF system, the H 2 H Module takes a portion of the fresh dialysate from the host machine (e.g. 200 ml/min) and purifies it for infusion into the blood side of the MD 220 filter. As a result, the dialysate %ow entering the MD 220 filter ( filter dialysate ) is reduced by the volume of infusion %uid (200 ml/ min). Therefore, in this example, the filter dialysate would be 600 ml/min. As a result of this lower filter inlet dialysate %ow rate (600 ml/min), the diffusive clearance of the MD 220 filter may be less than the diffusive clearance of a conventional dialyzer that would receive the full 800 ml/min dialysate inlet %ow. However, the MD 220 filter has a convective clearance component due to the 200 ml/min infusion %ow rate. As a result, the overall clearance of the MD 220 filter is equal to or greater than that of a conventional dialyzer at the same host machine Q d setting. On-line Mid-Dilution HDF with UF Rate Set = 0 Female & Male Hansen Connectors Module Replacement Fluid (200 ml/min) Water Machine Fresh Dialysate 800 ml/min Pump Filter Dialysate (600 ml/min) OLp r MD 220 HDF Filter Concentrates UF Pump Spent Dialysate (600 ml/min) Ultrafiltrate (200 ml/min) Blood Blood from Patient (400 ml/min) Circuit Dialysis Patient Drain Blood to Patient (400 ml/min) No Net Fluid Loss On-line Mid-Dilution HDF with UF Rate = 1.2 L/hr H 2H Module Dialysis Machine Water OLp r MD 220 HDF Filter Drain Clinicians Overview with Safety and Efficacy Summary 7
8 The Clinical Study The Study Results A multi-center, non-randomized clinical study was performed under an investigational device exemption (IDE) to evaluate safety and efficacy of the Nephros On-line Mid- Dilution Hemodiafiltration System. 28 patients who had been receiving maintenance high-%ux hemodialysis for a minimum of 3 months entered the test phase of the study using the Nephros OLpūr H 2 H Hemodiafiltration Module, its accessory components, and the Nephros OLpūr MD 220 Hemodiafilter. A four (4) week period of routine high-%ux hemodialysis (without reuse) with dialysate %ow rate (Q d ) ranging between 600 to 800 ml/ min with an average treatment time (95% CI) of approximately 230 min (219; 241) served as a control (baseline) period for comparison purposes. Patients then received 12 weeks of on-line HDF therapy on the Nephros Hemodiafiltration System devices at similar dialysate %ow rates (Q d ) and treatment times with an average substitution %uid %ow rate (95% CI) of approximately 185 ml/min (177;193) whereby similar data was collected during this period as the control period. Conventional dialysate was used as input to the H 2 H Module and MD 220 filter during this clinical study, this representing a worse case condition relative to its intended use with ultrapure dialysate as input to the H 2 H Module and MD 220 filter. The primary objective of this study was to verify safety and clinical tolerance associated with performing on-line HDF with the Nephros MD 220 Hemodiafilter and the Nephros H 2 H Module in conjunction with an approved (standard UF-controlled) host hemodialysis machine. This objective was measured by comparing the total number of inter- and intra-dialytic adverse events (AEs) and intra-dialytic adverse symptoms occurring over each study period. The secondary objective of this study was to monitor subject blood chemistries, including beta-2-microglobulin and C-reactive protein (as an in%ammatory marker), and traditional performance parameters for determining adequacy of dialysis. In addition, Quality of Life assessments (Kidney Disease and Quality of Life (KDQOL -36) were obtained during the fourth week of the control period (between visits 10 and 12) and during the final week of the test period (between visits 46 and 48). The study demonstrated non-inferiority of treatment with the test device, Nephros OLpūr MD 220 Hemodiafilter and Nephros OLpūr H 2 H Module in conjunction with a standard UF-controlled hemodialysis machine, to the standard control device (see table below). Reduction of beta-2-microglobulin with the test device was found to be significantly greater than that with the control device. Overall, use of the test device was safe and welltolerated. Adverse Events and Adverse Symptoms The ITT (intent-to-treat) population included all subjects who underwent treatment at least once, which was used for all analyses. For the primary parameters Adverse Event Rate (AER) and Adverse Symptom Rate (ASR), a PP (per-protocol) analysis in addition to the ITT analysis was performed. No subjects were excluded, but intra-dialytic AEs and adverse symptoms were excluded only if they occurred following dialysis performed without the test device during the test period. 8 Nephros On-line Mid-Dilution Hemodiafiltration System
9 All AEs were analyzed according to the treatment-emergent principle in which an event was reported in the phase where it emerged (i.e., started a(er baseline or worsened versus baseline in the attributes severity, seriousness, relation to device, or action taken regarding the device), and not in the subsequent phases, even if the event continued to be present. Unless indicated otherwise, AEs and abnormalities discussed are treatmentemergent. Control Period Rate Test Period Rate Observed difference between test and control periods 95% CI on difference Result a AER b inclusion of hypo/ hyper volemic events ITT analysis ; non-inferior PP analysis ; non-inferior AER b exclusion of hypo/hyper volemic events ITT analysis ; non-inferior PP analysis ; non-inferior ASR b ITT analysis ; non-inferior PP analysis ; non-inferior a Non-inferiority of the test device to the control device was concluded if the upper confidence bound of the 95% CI interval was 0.02 for the difference in AER and 0.09 for the difference in ASR. b The AER and ASR are the total number of AEs or adverse symptoms, respectively, in each study period divided by the total number of treatments in each study period. Overall, all subjects were reported with at least one AE during both the control and the test period. Most of the AEs were intra-dialytic; only 9 (27%) subjects had an inter-dialytic AE during the 4-week control period and 8 (29%) subjects during the 12- week test period. Most of the intra-dialytic AEs concerned procedural complications (all subjects in the control and test period), which were mainly hemodialysis-induced symptoms, (i.e., hypovolemia and hypervolemia) which was based on a narrow tolerance around a measured subject %uid balance UF Error. Other reported intra-dialytic AEs were device leakage and procedural complication. Inter-dialytic AEs were mostly infections and gastrointestinal disorders. Nineteen (57.6%) and 16 (57.1%) subjects were reported with at least one adverse symptom in the control and test period, respectively. Cramping and hypotensive episodes were the most frequently reported adverse symptoms in both treatment periods. Hypotensive episodes occurred at a 12% incident rate during the test period compared to an 8% incident rate during the control period. Most AEs (intra- and inter-dialytic) were mild in severity. Moderate intra- and inter-dialytic AEs were reported for 1 subject each during the control period; none were reported in the test period. During the control period, severe inter-dialytic AEs were reported for 2 subjects (supraventricular tachycardia, upper gastrointestinal hemorrhage, chest pain, pain, staphylococcal bacteremia, and %ank pain), and no severe intra-dialytic AEs were reported. During the test period, severe intra-dialytic AEs were reported for 1 subject (catheter sepsis) and severe inter-dialytic AEs for 2 subjects (cellulitis and arteriovenous fistula aneurysm). None of the subjects who received treatment with the test device expired. Only Clinicians Overview with Safety and Efficacy Summary 9
10 one subject expired during the control period. Five other subjects experienced other SAEs: 2 during the control period (inter-dialytic supraventricular tachycardia and lobar pneumonia) and 3 subjects during the test period (1 intra-dialytic catheter sepsis and 2 inter-dialytic cellulitis and arteriovenous fistula aneurysm). Study treatment was permanently stopped due to an inter-dialytic SAE for 3 subjects during the control period and for 1 subject during the test period due to the hospitalization criteria outlined in the study protocol. Lab Results There were no consistent changes over time in mean laboratory values, except for a decrease in mean Alkaline Phosphatase (pre-treatment), beta-2-microglobulin (pretreatment), and beta-2-microglobulin (post-treatment) levels. Between group comparison of the results obtained at Week 4 during the control period with those at Week 8, 12, and 16 during the test period, showed that for URR, Kt/Vdp, and PCR n the difference was not statistically significant (p > 0.05). For β 2 m RR, the between group difference was statistically significantly different (< 0.001) in favor of the use of the Nephros test device at all 3 laboratory assessments. Kt/Vdp values in both the test and control periods were approximately 1.5 on average. While these values are above the NKF KDOQI guidelines, they are not a necessary target for use of the Nephros HDF. They simply re%ect the standard practices of the clinics involved in the study. Lab results appear below. Lab Test Mean Week 4 Dialysis Mean Week 8 HDF Mean Week 12 HDF Mean Week 16 HDF Albumin (g/dl) Alkaline Phosphatase (u/l) Beta 2 Microglobulin (mg/l) PRE Beta 2 Microglobulin (mg/l) POST Bicarbonate (mmol/l) Blood Urea Nitrogen (mg/dl) PRE Blood Urea Nitrogen (mg/dl) POST C-Reactive Protein (mg/dl) Calicium (mg/dl) Chloride (mmol/l) Creatinine (mg/dl) Ferritin (ng/ml) Hematocrit (%) Hemaglobin (g/dl) Iron (ug/dl) Lactate Dehyrogenase (u/l) Magnesium (mg/dl) Phosphorus (mg/dl) Platelet Count (X103) Potassium (mmol/l) Sodium (mmol/l) Total Protein (g/dl) PRE Total Protein (g/dl) POST White Blood Count (X103) Nephros On-line Mid-Dilution Hemodiafiltration System
11 Treatment Efficacy Mean Week 4 Dialysis Mean Week 8 HDF Mean Week 12 HDF Mean Week 16 HDF Urea Reduction Ratio KT/Vdp Protein Catabolic Rate Beta-2-m Reduction Ratio Quality of Life- KDQOL -36 The burden of kidney disease was assessed as low in comparison with the symptoms, problems, and effects of the disease. No statistical significant difference was observed between the control and test period for burden, symptoms and problems, and effects of kidney disease. Risk versus Benefit Statement Summarization of the clinic trial data in the section above and compliance of the Nephros devices with pertinent design safety standards indicates the Nephros Online Mid-Dilution Hemodiafiltration System adds no additional risk for patients or users when compared to standard high-%ux hemodialysis; however, the clinical trial data showed that hypotensive episodes occurred at a 12% incident rate during the hemodiafiltration test period compared to an 8% rate during the standard high-%ux hemodialysis control period. The clinical trial data also indicated that with hemodiafiltration there is a significant improvement in the removal of the middlemolecular weight toxin beta-2-microglobulin when compared to standard high-%ux hemodialysis. As such, we believe the benefits of on-line HDF with the Nephros On-line Mid-Dilution Hemodiafiltration System outweigh the risks associated with its use. First treatment performed with the Nephros On-line Mid-Dilution Hemodiafiltration System. Shown are Dr. Leonard Stern (left) and Edward Spence (right). Clinicians Overview with Safety and Efficacy Summary 11
12 Nephros Nephros, Inc. 380 Lackawanna Place South Orange, New Jersey USA Telephone: Fax: Rev.01
Modes of Extracorporeal Therapies For ESRD Patients
Modes of Extracorporeal Therapies For ESRD Patients Suhail, MD Extracorporeal Therapies: Dialytic Therapies Dialysis: Movement of molecules across a semipermeable membrane (Bi-directional) Movement of
More informationMEDICAL EQUIPMENT II HEMODIALYSIS
MEDICAL EQUIPMENT II - 2012 HEMODIALYSIS Lecture 1 Prof. Yasser Mostafa Kadah Hemodialysis Machines Single-patient hemodialysis machines deliver a patient s dialysis prescription by controlling blood and
More informationPhysiology of Blood Purification: Dialysis & Apheresis. Outline. Solute Removal Mechanisms in RRT
Physiology of Blood Purification: Dialysis & Apheresis Jordan M. Symons, MD University of Washington School of Medicine Seattle Children s Hospital Outline Physical principles of mass transfer Hemodialysis
More informationHEMODIALFILTRATION LITERATURE REVIEW AND PRACTICE CONSIDERATIONS 1.0 PRACTICE CONSIDERATIONS 2.0 CURRENT LITERATURE REVIEW
HEMODIALFILTRATION LITERATURE REVIEW AND PRACTICE CONSIDERATIONS This document was prepared at the request of the BC Hemodialysis Committee to provide a brief overview of the literature and to identify
More informationCRRT Fundamentals Pre- and Post- Test. AKI & CRRT Conference 2018
CRRT Fundamentals Pre- and Post- Test AKI & CRRT Conference 2018 Question 1 Which ONE of the following statements regarding solute clearance in CRRT is MOST correct? A. Convective and diffusive solute
More informationCRRT Fundamentals Pre-Test. AKI & CRRT 2017 Practice Based Learning in CRRT
CRRT Fundamentals Pre-Test AKI & CRRT 2017 Practice Based Learning in CRRT Question 1 A 72-year-old man with HTN presents to the ED with slurred speech, headache and weakness after falling at home. He
More informationChapter 8 Online Hemodiafiltration by Fresenius Medical Care
Chapter 8 Online Hemodiafiltration by Fresenius Medical Care Bernard Canaud, Pascal Kopperschmidt, Reiner Spickermann, and Emanuele Gatti Abstract Hemodiafiltration has been identified by Fresenius Medical
More informationHDx THERAPY. Enabled by. Making possible personal.
HDx THERAPY Enabled by Making possible personal. THE NEXT HORIZON IN DIALYSIS IS CLOSER THAN YOU THINK PHOSPHATE UREA HDx BY THERANOVA EXPANDS YOUR RENAL POSSIBILITIES The new HDx therapy (expanded HD)
More informationImplementing therapy-delivery, dose adjustments and fluid balance. Eileen Lischer MA, BSN, RN, CNN University of California San Diego March 6, 2018
Implementing therapy-delivery, dose adjustments and fluid balance. Eileen Lischer MA, BSN, RN, CNN University of California San Diego March 6, 2018 Objectives By the end of this session the learner will
More informationTREATMENT SAFETY AND EFFECTIVENESS CONTROL OF MODERN DIALYSIS MACHINES
TREATMENT SAFETY AND EFFECTIVENESS CONTROL OF MODERN DIALYSIS MACHINES Sarajevo, October 5 th, 2017 Modern dialysis machines have evolved from the early cumbersome and inefficient devices to those with
More information28-Feb-10 Reza Sabagh
DIALYSIS EQUIPMENTS (DIALYSIS MACHINE & R.O) Nursing Conference on Dialysis Tehran 1 The standard dialysis machines are designed for performing chronic and acute hemodialysis. They can be used in home
More informationUAB CRRT Primer Ashita Tolwani, MD, MSc University of Alabama at Birmingham
UAB CRRT Primer 2018 Ashita Tolwani, MD, MSc University of Alabama at Birmingham 1 CRRT Primer Continuous Renal Replacement Therapy (CRRT) is a "catch all" term used for all the continuous modes of renal
More informationHEMODIAFILTRATION PRINCIPLES AND ADVANTAGES OVER CONVENTIONAL HD PRESENTATION BY DR.ALI TAYEBI
HEMODIAFILTRATION PRINCIPLES AND ADVANTAGES OVER CONVENTIONAL HD PRESENTATION BY DR.ALI TAYEBI high-flux Hemodiafiltration (HDF) Combination of two dialysis techniques, hemodialysis and hemofiltration:
More informationDrug Use in Dialysis
(Last Updated: 08/22/2018) Created by: Socco, Samantha Drug Use in Dialysis Drambarean, B. (2017). Drug Use in Dialysis. Lecture presented at PHAR 503 Lecture in UIC College of Pharmacy, Chicago. DIALYSIS
More informationHemodiafiltration in Europe : Trends, Practices, Outcomes & Perspectives
Hemodiafiltration in Europe : Trends, Practices, Outcomes & Perspectives Prof. Bernard Canaud Nephrology, Dialysis and Intensive Care Lapeyronie Hospital CHRU Montpellier - France Opening remarks and special
More informationKidney Failure. Haemodialysis
Kidneys & Kidney Failure 2 Haemodialysis This booklet will help you to know the process of Haemodialysis in detail. It will also tell you about the disposables of Haemodialysis. In the end the advantages
More informationKaren Mak R.N. (Team Leader) Renal Dialysis Centre Hong Kong Sanatorium & Hospital
Karen Mak R.N. (Team Leader) Renal Dialysis Centre Hong Kong Sanatorium & Hospital - Renal Transplantation - Peritoneal Dialysis - Extracorporeal Therapy Extracorporeal Therapy It is the procedure in
More informationEFFECT OF ONLINE HAEMODIAFILTRATION ON ALL- CAUSE MORTALITY AND CARDIOVASCULAR OUTCOMES Ercan Ok, Izmir, Turkey
EFFECT OF ONLINE HAEMODIAFILTRATION ON ALL- CAUSE MORTALITY AND CARDIOVASCULAR OUTCOMES Ercan Ok, Izmir, Turkey Chair: Walter H. Hörl, Vienna, Austria Wojciech Zaluska, Lublin, Poland Prof Ercan Ok Division
More informationHaemodialysis Machines H/S Visually the best dialysis results
Haemodialysis Machines 4008 H/S Visually the best dialysis results Therapy Through continuous optimisation of the treatment modalities Fresenius Medical Care always aims to offer patients the best renal
More information*Sections or subsections omitted from the full prescribing information are not 6 ADVERSE REACTIONS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and
More informationNew method of blood purification (Recycle Filtration System)
Tokai J Exp Clin Med., Vol. 33, No. 3, pp. 124-129, 2008 New method of blood purification (Recycle Filtration System) Hajime SUZUKI 1), Miho HIDA 1), Makoto KITAMURA 1), Shin-ichi TANAKA 2), Takayo MIYAKOGAWA
More informationDialysers Increasing Cost and Treatment Efficiency
Haemodialysis Dialysers Increasing Cost and Treatment Efficiency Fluid Substitution Calculator Content Haemodialysis yesterday 3 Haemodialysis today 4 Dialyser selection criteria 5 Relation of blood flow
More informationEnhancement of convective transport by internal filtration in a modified experimental hemodialyzer Technical Note
Kidney International, Vol. 54 (1998), pp. 979 985 Enhancement of convective transport by internal filtration in a modified experimental hemodialyzer Technical Note CLAUDIO RONCO, GIANCARLO ORLANDINI, ALESSANDRA
More informationDialysis System DBB-07
Dialysis System DBB-07 The flexible solution Innovations for Human Care. 0123 Times are changing, we have the solution. DBB-07 Dialysis System The challenge The demand of dialysis treatment methods should
More informationHemodialysis today has evolved
Lessons in Dialysis, Dialyzers, and Dialysate Robert Hootkins, MD, PhD The author is Chief of Nephrology and Hypertension at The Austin Diagnostic Clinic, Austin, Texas. He is also a member of D&T s editorial
More informationHemodialysis is a life-sustaining procedure for the treatment of
The Dialysis Prescription and Urea Modeling Biff F. Palmer Hemodialysis is a life-sustaining procedure for the treatment of patients with end-stage renal disease. In acute renal failure the procedure provides
More informationAK 200 S AK 200 ULTRA S. A better way to better care
AK 200 S AK 200 ULTRA S A better way to better care The AK 200 series state-of-the-art solutions for improving dialysis treatment As a global leader in dialysis, Gambro is committed to making a difference
More informationReference ID:
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PRISMASOL and PHOXILLUM safely and effectively. See full prescribing information for PRISMASOL and
More informationTJF-160F/VF Cleaning and Disinfection Checklist
TJF-160F/VF Cleaning and Disinfection Checklist TJF-160F/VF Cleaning and Disinfection Checklist This checklist is used to evaluate and confirm if cleaning and disinfection of the TJF-160F/VF has been performed
More informationLesson #7: Quality Assessment and Performance Improvement
ESRD Update: Transitioning to New ESRD Conditions for Coverage Student Manual Lesson #7: Quality Assessment and Performance Improvement Learning Objectives At the conclusion of this lesson, you will be
More informationIN THE NAME OF GOD Uremic toxins I. Small (< 500 D); water soluble Surrogate marker urea or sodium (ionic dialysance) Rapidly produced in intracellular fluid compartment Large variability in intra-patient
More informationModule 7 Your Blood Work
Module 7 Your Blood Work Every month you will need to collect a sample of your blood just before you start dialysis, and depending on your doctor s recommendation, at the end of your dialysis treatment.
More informationHemodiafiltration in BC Current Status and Obstacles Myriam Farah, MD, FRCPC
2015 emodiafiltration in BC Current Status and Obstacles Myriam Farah, MD, FRCPC OUTLINE What Why ow Why Not What Now No financial disclosures. DF = D and igh volume ULTRAFILTRATION to achieve convective
More informationCRRT Fundamentals Pre- and Post- Test Answers. AKI & CRRT 2017 Practice Based Learning in CRRT
CRRT Fundamentals Pre- and Post- Test Answers AKI & CRRT 2017 Practice Based Learning in CRRT Question 1 A 72-year-old man with HTN presents to the ED with slurred speech, headache and weakness after falling
More informationDiacap. Constant performance resulting in high quality dialysis. Avitum
Diacap Constant performance resulting in high quality dialysis Avitum B. Braun Avitum. Always with Passion. B. Braun is a leading international company in the healthcare market. With a long tradition stretching
More informationHaemodialysis. 4008S Visually the best dialysis results
Haemodialysis 4008S Visually the best dialysis results Therapy Through continuous optimisation of the treatment modalities Fresenius Medical Care always aims to offer patients the best renal replacement
More informationCrit-Line Monitor. Frequently Asked Questions
Crit-Line Monitor Frequently Asked Questions Crit-Line Monitor Frequently Asked Questions 1 What is the indication for use of the Crit-Line monitor? The Crit-Line Monitor III is used to non-invasively
More informationINSPIRED BY LIFE B. BRAUN DIALYZERS
INSPIRED BY LIFE B. BRAUN DIALYZERS OUR COMMITMENT. FOR LIFE. The Diacap Pro and xevonta dialyzers offer a broad range of high-quality dialyzers for individual treatment needs. It began in 1839, inspired
More informationObjectives. Peritoneal Dialysis vs. Hemodialysis 02/27/2018. Peritoneal Dialysis Prescription and Adequacy Monitoring
Peritoneal Dialysis Prescription and Adequacy Monitoring Christine B. Sethna, MD, EdM Division Director, Pediatric Nephrology Cohen Children s Medical Center Associate Professor Hofstra Northwell School
More informationIN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2001
IN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2001 [Before completing please read instructions at the bottom of this page and on pages 4 and 5] PATIENT IDENTIFICATION MAKE
More informationCONTINUOUS RENAL REPLACEMENT THERAPY (CRRT)
TABLE OF CONTENTS The purpose of this practice support document is to outline the procedures and guidelines related to care of the patient having continuous renal replacement therapy (CRRT) in the pediatric
More informationDialysis technologies
Moscow Institute of Electronic Technology Dialysis technologies Kidneys Remove toxic by-products of the metabolism and molecules smaller than 69000Da Regulate body fluid composition and volume Provide
More informationActive UMMC Protocols
UMMC CRRT 2018 Active UMMC Protocols 1. Standard CRRT Protocol PrismaFlex & NxStage CVVH with Fixed Ratio Regional Citrate Anticoagulation 2. No Anticoagulation Protocol PrismaFlex & NxStage CVVH with
More informationFundamentals of DIALYSIS
Fundamentals of DIALYSIS Knowing Your Kidneys Healthy Kidneys are the body s cleaning crew These are twin bean shaped organs, of the size of fist They make up a filter system for the blood & reabsorb almost
More informationECMO & Renal Failure Epidemeology Renal failure & effect on out come
ECMO Induced Renal Issues Transient renal dysfunction Improvement in renal function ECMO & Renal Failure Epidemeology Renal failure & effect on out come With or Without RRT Renal replacement Therapy Utilizes
More informationEnd-Stage Renal Disease. Anna Vinnikova, M.D. Associate Professor of Medicine Division of Nephrology
End-Stage Renal Disease Anna Vinnikova, M.D. Associate Professor of Medicine Division of Nephrology ESRD : Life with renal replacement therapy CASE: 18 month old male with HUS develops ESRD PD complicated
More informationReverse mid-dilution: new way to remove small and middle molecules as well as phosphate with high intrafilter convective clearance
Nephrol Dial Transplant (2007) 22: 2000 2005 doi:10.1093/ndt/gfm101 Advance Access publication 3 April 2007 Original Article Reverse mid-dilution: new way to remove small and middle molecules as well as
More informationUW MEDICINE PATIENT EDUCATION. Peritoneal Dialysis. A treatment option for kidney disease. There are 2 types of PD: continuous ambulatory
UW MEDICINE PATIENT EDUCATION Peritoneal Dialysis A treatment option for kidney disease Class Goals 1. Understand the purpose and basic principles of continuous ambulatory peritoneal dialysis (CAPD). 2.
More informationBPG 03: Continuous Renal Replacement Therapy (CRRT)
BPG 03: Continuous Renal Replacement Therapy (CRRT) Statement of Best Practice Patient s requiring Continuous Renal Replacement Therapy (CRRT) will receive appropriate therapy to meet their individual
More informationSt George Hospital Renal Department Guideline: INTERNAL ONLY ANTICOAGULATION - COMMENCEMENT OF HAEMODIALYSIS
ANTICOAGULATION - COMMENCEMENT OF HAEMODIALYSIS Summary Aim: To prevent clotting of the extracorporeal circuit during haemodialysis If there are no contraindications, heparin can be used. In the first
More informationThere are no shortcuts to Dialysis
There are no shortcuts to Dialysis 1 Outcomes John Sweeny Wednesday, March 21 st, 2018 (3:10 pm 4:10 pm) 2 Quality in Hemodialysis Quality Health Care is the degree to which health services increases the
More informationIN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006
IN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006 PATIENT IDENTIFICATION [Before completing please read instructions at the bottom of this page and on pages 5 and 6] MAKE
More informationPackage leaflet: information for the user. Prismasol 2 mmol/l Potassium Solution for haemodialysis/haemofiltration
Package leaflet: information for the user Prismasol 2 mmol/l Potassium Solution for haemodialysis/haemofiltration Calcium chloride dihydrate/ magnesium chloride hexahydrate/ glucose monohydrate/ lactic
More informationClinical Performance Goals
Clinical Performance Goals 2011-2012 Clinical Performance Goals 2011-2012 Table of Contents Table of Contents... 1 Health Care Quality Improvement Program... 2 Clinical Performance Measures... 6 Chapter
More informationMODALITIES of Renal Replacement Therapy in AKI
MODALITIES of Renal Replacement Therapy in AKI Jorge Cerdá, MD, MS, FACP, FASN Clinical Professor of Medicine Albany Medical College Albany, NY, USA cerdaj@mail.amc.edu In AKI, RRT is a multidimensional
More informationUNDERSTANDING THE CRRT MACHINE
UNDERSTANDING THE CRRT MACHINE Helen Dickie Renal Sister Critical Care Unit Guy s and St.Thomas NHS Foundation Trust 18.10.14 RRT options - IHD vs CRRT (1) Intermittent HaemoDialysis e.g. 4hrs daily or
More information2019 Home Hemodialysis Standing Orders
2019 Home Hemodialysis Standing Orders 1. Nutrition Standards of Care: A. Follow P&P Nutrition Standards of Care 2. Laboratory Tests: A. Drawn On Admission: 1. Renal Function Panel (BMP, PO 4 and Albumin)
More informationRENAL. Cellentia -H. Cellulose triacetate, single-use, hollow-fiber, high-flux hemodialyzer.
RENAL Cellentia -H Cellulose triacetate, single-use, hollow-fiber, high-flux hemodialyzer www.nipro.com Confidence from the inside out 30 R & D Industry expertise Trusted worldwide Innovative solutions
More informationPORTO 2 VENT CPAP OS. Operator s Manual. PORTO 2VENT CPAP OS System Operator s Manual Part Number Rev I
PORTO 2 VENT CPAP OS Operator s Manual 1 2 TABLE of CONTENTS 1. Introduction 3. Operating Instructions 1a. Definitions 3a. Setting the CPAP Level 1b. General Description 3b. Applying the Breathing Circuit
More informationDiagnosis: Allergies with reaction type:
Patient Name: Diagnosis: Allergies with reaction type: CHRONIC HOME HEMODIALYIS ORDERS Version 4 1/21/2013 1. TREATMENT ORDERS A. Frequency of treatment 5 6 times per week. B. Weight and blood pressures,
More informationAchieve. Achieve. More Effective. Dialysis Treatment
Achieve More Effective Achieve Dialysis Treatment The Crit-Line monitor measures the following: Real-time, lab-equivalent, non-invasive hematocrit (HCT) Real-time percent changes in intravascular blood
More informationONLINE HEMODIALYSIS TRAINING SESSION 1
ONLINE HEMODIALYSIS TRAINING SESSION 1 This document is a supplement to the Online Training. Do not reproduce. Copyright Dialysis4Career. All Rights Reserved. The Renal System - A highly sophisticated
More informationMaking possible personal.
Making possible personal. HDX THERAPY, ENABLED BY THE THERANOVA DIALYZER HDF PERFORMANCE AND BEYOND AS SIMPLE AS HD The THERANOVA dialyzer, featuring an innovative membrane, effectively targets large middle
More informationContinuous Renal Replacement Therapy. Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD
Continuous Renal Replacement Therapy Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD 1 Definition of Terms SCUF - Slow Continuous Ultrafiltration
More informationHemodiafiltration: practical points. Rukshana Shroff Great Ormond Street Hospital for Children London, UK
Hemodiafiltration: practical points Rukshana Shroff Great Ormond Street Hospital for Children London, UK Effectiveness of RRT modalities Mcfarlane, Seminars in dialysis, 2009 No benefit from increased
More informationStaff-Assisted Home Hemodialysis
Medical Coverage Policy Staff-Assisted Home Hemodialysis Table of Contents Coverage Policy... 1 Overview... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date...11/15/2017
More informationContinuous Renal Replacement Therapy
Continuous Renal Replacement Therapy Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD Definition of Terms SCUF - Slow Continuous Ultrafiltration
More informationRenal Replacement Therapy in ICU. Dr. Sunil Sharma Senior Resident Dept of Pulmonary Medicine
Renal Replacement Therapy in ICU Dr. Sunil Sharma Senior Resident Dept of Pulmonary Medicine Introduction Need for RRT in patients with ARF is a common & increasing problem in ICUs Leading cause of ARF
More informationmultibic potassium-free multibic 2 mmol/l potassium multibic 3 mmol/l potassium multibic 4 mmol/l potassium
FRESENIUS MEDICAL CARE Deutschland GmbH Name(s) of the medicinal product(s): -free 2 mmol/l 3 mmol/l 4 mmol/l Pharmaceutical form: Solution for haemodialysis/haemofiltration Procedure number(s): DE/H/0388/001-004/II/030/G
More informationDrivers have GPS. Dialysis Patients have. Making possible personal.
Drivers have GPS Dialysis Patients have with The Amia System with Sharesource Connectivity Platform. For step-by-step navigation of home peritoneal dialysis. Please see indications for use on the back
More information- SLED Sustained Low-Efficiency Dialysis
Continuous Renal Replacement Therapy Gregory M. Susla, Pharm.D., F.C.C.M. Associate Director, Medical Information MedImmune, LLC Gaithersburg, MD 1 Definition of Terms - SCUF - Slow Continuous Ultrafiltration
More informationHemodialysis Adequacy: A Complex and Evolving Paradigm. Balazs Szamosfalvi, MD Monday, 08/30/ :00-09:45
Hemodialysis Adequacy: A Complex and Evolving Paradigm Balazs Szamosfalvi, MD Monday, 08/30/2010 09:00-09:45 Adequacy 1943-1970 Fresenius The patient survived the dialysis session Uremia improved Volume
More informationVaxcel Implantable Ports Valved and Non-Valved. A Patient s Guide
Vaxcel Implantable Ports Valved and Non-Valved A Patient s Guide Vaxcel Implantable Port This pamphlet provides some answers to questions you may have about your implantable port and how to care for it
More informationPortable Equine Nebuliser System. User Manual
Portable Equine Nebuliser System User Manual Table of Contents INTENDED USE... 3 SAFETY INFORMATION... 3 TECHNICAL SPECIFICATION... 4 INSTRUCTIONS FOR USE... 6 MAINTENANCE... 12 TROUBLESHOOTING... 13 WARRANTY...
More informationDialysis, personalized. More options for your patients well being.
Dialysis, personalized. More options for your patients well being. Discover the advanced peritoneal dialysis (PD) system with improved features for added control and convenience during your patients treatment
More informationChemistry Reference Ranges and Critical Values
Alanine Aminotransferase (ALT, SGPT) 3-9 years 9-18 years 1-9 years 9-18 years 10-25 U/L 10-35 U/L 10-30 U/L 10-25 U/L 10-30 U/L 10-35 U/L 10-25 U/L 10-35 U/L 10-25 U/L 10-20 U/L 10-35 U/L Albumin 0-6
More informationChemistry Reference Ranges and Critical Values
Alanine Aminotransferase (ALT, SGPT) 3-9 years 9-18 years 1-9 years 9-18 years 10-30 U/L 10-30 U/L 10-20 U/L Albumin 0-6 days 6 days - 37 months 37 months - 7 years 7-20 years 2.6-3.6 g/dl 3.4-4.2 g/dl
More informationWales Critical Care & Trauma Network (North) CITRATE GUIDELINES (Approved May 2015)
Wales Critical Care & Trauma Network (North) CITRATE GUIDELINES (Approved May 2015) BCU Citrate Guideline v6 Nov 2015 (Approved by CCSC May 15) 1 BCU Critical Care Guideline for Renal Replacement Therapy
More informationSupplemental Quick Reference Guide
Supplemental Quick Reference Guide How to use this Supplemental Quick Reference Guide This guide provides a 5-step method for considering a variety of frequencies and treatment lengths, based on achieving
More information404FM.2 CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) USING CITRATE Target Audience: Hospital only ICU. (Based on Gambro and Kalmar Hospital protocols)
404FM.2 CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) USING CITRATE Target Audience: Hospital only ICU (Based on Gambro and Kalmar Hospital protocols) CRRT using regional citrate anticoagulation This is
More informationBiology Slide 1 of 36
Biology 1 of 36 38 3 The Excretory System 2 of 36 Functions of the Excretory System 1.Function: process which eliminates metabolic wastes 3 of 36 Functions of the Excretory System (The skin excretes excess
More informationPRESCRIBING INFORMATION. Prism0CAL B22K0/0. Sodium chloride 7.14 g/l, Magnesium chloride hexahydrate 3.05 g/l, Sodium hydrogen carbonate 2.
PRESCRIBING INFORMATION Prism0CAL B22K0/0 Sodium chloride 7.14 g/l, Magnesium chloride hexahydrate 3.05 g/l, Sodium hydrogen carbonate 2.12 g/l Sterile solution for hemodialysis, hemofiltration and hemodiafiltration
More informationNursing Care of the Dialysis Patient. Adrian Hordon, MSN, RN
Nursing Care of the Dialysis Patient Adrian Hordon, MSN, RN Understand principles of hemodialysis Recognize different access ports Identify side effects and complications Discuss nursing care for pre and
More informationUltrafiltration Programs : Clinical Experiences
Ultrafiltration Programs : Clinical Experiences By : Kay Woodruff, RN, BS, CNN, Divisional Clinical Specialist Lisa Miller Hedin, RN, CNN, Senior Clinical Specialist Introduction The purpose of this article
More informationGambro Renal Products Technical Assistance Services
Gambro Renal Products Technical Assistance Services http://tech.usa-gambro.com 800/525-2623 303/232-6800 Technical Update PH,TR,11060 12/2008 TROUBLESHOOTING Equipment Type: Phoenix Dialysis System Subject:
More informationDevice Preparation (all steps to be performed per standard interventional technique)
sertera Biopsy Device Instructions for Use Please read all information carefully. Failure to properly follow the instructions may lead to unintended consequences. Important: This package insert is designed
More informationSection 3: Prevention and Treatment of AKI
http://www.kidney-international.org & 2012 KDIGO Summary of ommendation Statements Kidney International Supplements (2012) 2, 8 12; doi:10.1038/kisup.2012.7 Section 2: AKI Definition 2.1.1: AKI is defined
More informationKit Assembly. Enhanced Simplicity OPERATIONAL BENEFITS. Automatic venous chamber adjustment. User friendly interface
System for CRRT Kit Assembly Enhanced Simplicity User friendly interface Flexible AcuSmart touch screen can be turned 180 degrees with up to 100 degrees of tilt in order to ensure visibility from various
More informationTherapeutic apheresis (introduction) Orieji Illoh, MD November 21, 2006
Therapeutic apheresis (introduction) Orieji Illoh, MD November 21, 2006 Apheresis Removal of blood Separation into component parts One component is retained and remainder is returned History First tried
More informationST. DOMINIC-JACKSON MEMORIAL HOSPITAL JACKSON, MISSISSIPPI. CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) HEPARIN ANTICOAGULATION Page 1 of 5
HEPARIN ANTICOAGULATION Page 1 of 5 Pharmacy Mnemonic: CRRTHEP1 PATIENT DATA: DIAGNOSIS: AKI ESRD Other: WEIGHT: Today: kg Admission Weight:: kg Dry Weight: kg Access TYPE: Temporary Dialysis Catheter
More informationCATHETER ACCESS KIT. For use with Prometra Programmable Infusion Systems
CATHETER ACCESS KIT Caution: Federal (USA) Law restricts this device to sale by or on the order of a physician. Table of Contents Contents... 3 Description... 3 Indications... 3 Contraindications... 3
More informationCan We Achieve Precision Solute Control with CRRT?
Can We Achieve Precision Solute Control with CRRT? Claudio Ronco, M.D. David Selewski, M.D. Rolando Claure-Del Granado, M.D. AKI & CRRT Conference February, 2019 Disclosures I have no actual or potential
More informationPERITONEAL DIALYSIS PRESCRIPTION MANAGEMENT GUIDE
PERITONEAL DIALYSIS PRESCRIPTION MANAGEMENT GUIDE TABLE OF CONTENTS Introduction.... 3 SECTION 1: FUNDAMENTALS OF THE PRESCRIPTION.... 4 Getting Started: Patient Pathway to First Prescription.... 5 Volume
More informationWhat is a PET? Although there are many types of pets, we will be discussing the Peritoneal Equilibration Test
1 2 3 What is a PET? Although there are many types of pets, we will be discussing the Peritoneal Equilibration Test 4 Background information about the PET 1983 Dr. Twardowski and colleagues began measuring
More informationNATIONAL QUALITY FORUM Renal EM Submitted Measures
NATIONAL QUALITY FORUM Renal EM Submitted Measures Measure ID/ Title Measure Description Measure Steward Topic Area #1662 Percentage of patients aged 18 years and older with a diagnosis of CKD ACE/ARB
More informationmean hemoglobin 11 g/dl (110 g/l) compared to patients with lower mean hemoglobin values (Table 20).
S44 Figure 53 depicts the trend in Epoetin dosing from the 1998 study period to the 2003 study period, with an increasing mean weekly Epoetin dose (units/kg/wk) for patients prescribed Epoetin in lower
More informationHemodiafiltration: principles and advantages over conventional HD. Rukshana Shroff Great Ormond Street Hospital for Children London, UK
Hemodiafiltration: principles and advantages over conventional HD Rukshana Shroff Great Ormond Street Hospital for Children London, UK Effectiveness of RRT modalities Mcfarlane, Seminars in dialysis, 2009
More informationEndoscopic Technology. Operating Manual. Cannula system
Endoscopic Technology Operating Manual AlphaPort Cannula system This manual contains proprietary information that is protected by copyright. All rights are reserved. This manual or excerpts thereof may
More informationSt. Jude Medical 8-Channel Adapter. Clinician's Manual
St. Jude Medical 8-Channel Adapter Clinician's Manual CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician. For U.S. California Only: Proposition 65, a State of California
More informationPatient Education Programme. Kidney Options Guiding you when kidneys fail
Patient Education Programme Kidney Options Guiding you when kidneys fail About the kidneys What do healthy kidneys do? Your two kidneys work more than you realise. The kidneys remove excess body water
More information